Anti-angiogenic properties of calcium trifluoroacetate

被引:2
|
作者
Bussolati, Benedetta [2 ]
Ribatti, Domenico [3 ]
Munaron, Luca [4 ]
Bartorelli, Alberto [5 ]
Bussolati, Gianni [1 ]
机构
[1] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy
[2] Univ Turin, Ctr Mol Biotechnol, Dept Internal Med, I-10126 Turin, Italy
[3] Univ Bari, Dept Human Anat & Histol, I-70121 Bari, Italy
[4] Univ Turin, Ctr Complex Syst Mol Biol & Med SyBioM, Nanostruct Interfaces & Surfaces Ctr Excellence N, Dept Anim & Human Biol, I-10126 Turin, Italy
[5] Univ Milan, I-20122 Milan, Italy
关键词
Angiogenesis; Calcium; Trifluoroacetate; NITRIC-OXIDE PRODUCTION; CHORIOALLANTOIC MEMBRANE; INTRACELLULAR CALCIUM; MECHANISMS; VEGF; PROLIFERATION;
D O I
10.1016/j.mvr.2009.07.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Endothelial cell proliferation and the formation of new vessels are strictly regulated by angiogenic factors (e.g., VEGF) that induce the activation of signal transduction pathways controlled by calcium dynamics. Using in vitro and in vivo experiments, we investigated the effect of calcium trifluoroacetate (CaTFAc), a complex, poorly dissociated salt that is characterized by its low toxicity, on angiogenesis. In vitro, CaTFAc inhibited VEGF-induced effects on endothelial cell proliferation. In two in vivo models of angiogenesis, a Matrigel plug in mice and a chick embryo chorioallantoic membrane, CaTFAc inhibited the VEGF-induced formation of new vessels. The exact mechanism of action is still under investigation, but in vitro experiments demonstrate that CaTFAc induced a reversible increase in the levels of intracellular calcium under basal conditions and prevented calcium signaling induced by VEGF. These results are the first to suggest that CaTFAc may be useful for the treatment of diseases caused by enhanced angiogenesis. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 50 条
  • [31] Responses to anti-angiogenic therapies
    Paller, AS
    JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2000, 5 (01) : 83 - 86
  • [32] Oligosaccharides as anti-angiogenic agents
    Cole, Claire Louise
    Jayson, Gordon C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (03) : 351 - 362
  • [33] Anti-angiogenic function of tocotrienol
    Miyazawa, Teruo
    Shibata, Akira
    Nakagawa, Kiyotaka
    Tsuzuki, Tsuyoshi
    ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 2008, 17 : 253 - 256
  • [34] Anti-angiogenic factors and preeclampsia
    Reyna-Villasmil, Eduardo
    AVANCES EN BIOMEDICINA, 2018, 7 (01): : 23 - 34
  • [35] Sales for anti-angiogenic drugs
    Ribatti, Domenico
    ONCOTARGET, 2017, 8 (24) : 38080 - 38081
  • [36] Anti-angiogenic effect of α-mangostin
    Shiozaki, Tomoko
    Fukai, Miyuki
    Hermawati, Elvira
    Juliawaty, Lia Dewi
    Syah, Yana Maolana
    Hakim, Euis Holisotan
    Puthongking, Ploenthip
    Suzuki, Toshihiro
    Kinoshita, Kaoru
    Takahashi, Kunio
    Koyama, Kiyotaka
    JOURNAL OF NATURAL MEDICINES, 2013, 67 (01) : 202 - 206
  • [37] Anti-angiogenic activities of chitooligosaccharides
    Wu, Haige
    Yao, Ziang
    Bal, Xuefang
    Du, Yuguang
    Lin, Bingcheng
    CARBOHYDRATE POLYMERS, 2008, 73 (01) : 105 - 110
  • [38] COMPLICATIONS OF ANTI-ANGIOGENIC THERAPY
    Brunetto, Andre
    Tan, Daniel
    Yap, Tim
    Olmos, David
    Kaye, Stan
    ANNALS OF ONCOLOGY, 2009, 20 : 24 - 24
  • [39] Anti-angiogenic strategy in cancerology
    Fons, P
    Malavaud, B
    Venat, L
    Plouet, J
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2000, 184 (03): : 579 - 587
  • [40] Dodging anti-angiogenic therapy
    Emma Greenwood
    Nature Reviews Cancer, 2002, 2 : 243 - 243